{"id":"W4286509886","doi":"10.1016/j.jhepr.2022.100544","title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","year":2022,"lang":"en","type":"article","venue":"JHEP Reports","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Toronto Liver Centre; University of Alberta","funders":"Novartis Institutes for BioMedical Research; Intercept Pharmaceuticals; Medical Research Council; Merck; Dr. Falk Pharma; GlaxoSmithKline; National Institute for Health and Care Research; Novartis; Pfizer","keywords":"Ursodeoxycholic acid; Tolerability; Placebo; Medicine; Discontinuation; Internal medicine; Obeticholic acid; Adverse effect; Cholestasis; Gastroenterology; Primary biliary cirrhosis; Farnesoid X receptor; Agonist; Receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00176682,0.0010634,0.002825351,0.0003003402,0.0003214151,0.0007105014,0.0005786614,0.001297548,0.004641425],"category_scores_gemma":[0.001617618,0.0006426041,0.001592874,0.0002911312,0.0007898818,0.0006593952,0.0003165679,0.001718522,0.0005652803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004146392,"about_ca_system_score_gemma":0.0008645131,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008133925,"about_ca_topic_score_gemma":0.001877327,"domain_scores_codex":[0.9994007,0.0003615782,0.00004742435,0.00006914958,0.00003722014,0.00008395082],"domain_scores_gemma":[0.9991423,0.000260532,0.0001872006,0.00007286479,0.00007077016,0.0002662893],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9766452,0.003978443,0.0004239505,0.0007602199,0.0005382555,0.00005882656,0.00004880895,0.0001798313,0.006140653,0.00004721765,0.0003517423,0.01082691],"study_design_scores_gemma":[0.912094,0.08524387,0.001523469,0.00002586297,0.0002263561,0.00003646582,0.00001727146,0.0001338278,0.0003362843,0.00002842424,0.0003259508,0.000008137858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989149,0.004739552,0.0005061083,0.0005232632,0.0003993861,0.003010879,0.0005412369,0.00009132885,0.001039195],"genre_scores_gemma":[0.9853988,0.005190915,0.001117105,0.0007561516,0.0004374818,0.003421505,0.0008622285,0.00001689246,0.002798897],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004641425,"threshold_uncertainty_score":0.01552707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00779975170173277,"score_gpt":0.2178358120458716,"score_spread":0.2100360603441388,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}